About Bausch + Lomb Corp
Ticker
info
BLCO
Trading on
info
NYSE
ISIN
info
CA0717051076
Industry
info
Medical Instruments & Supplies
Sector
info
Healthcare
CEO
info
Brenton L. Saunders J.D.
Headquarters
info
520 Applewood Crescent, Vaughan, ON, Canada, L4K 4B4
Employees
info
13,500
Website
info
bausch.com
Bausch + Lomb Corporation operates as an eye health company in the United States, Puerto Rico, China, France, Japan, Germany, the United Kingdom, Canada, Russia, Spain, Italy, Mexico, Poland, and internationally. It operates in three segments: Vision Care, Pharmaceuticals, and Surgical. The Vision Care segment provides contact lens that covers the spectrum of wearing modalities, including daily disposable and frequently replaced contact lenses; and contact lenses that are indicated for therapeutic use and provides optical correction during healing. It also offers contact lens care products, eye vitamins, mineral supplements, and over-the-counter eye drops that address various conditions, such as eye allergies, conjunctivitis, dry eye, and redness relief. The Pharmaceuticals segment offers proprietary and generic pharmaceutical products for post-operative treatments, as well as for the treatment of glaucoma, eye inflammation, ocular hypertension, dry eyes, and retinal diseases. The Surgical segment provides medical device equipment, consumables, and technologies for the treatment of cataracts, corneal, vitreous, and retinal eye conditions; and intraocular lenses and delivery systems, phacoemulsification equipment, and other surgical instruments and devices for cataract surgery. The company sells its products and services through direct sales forces and independent distributors. Bausch + Lomb Corporation was founded in 1853 and is headquartered in Vaughan, Canada. Bausch + Lomb Corporation operates as a subsidiary of Bausch Health Companies Inc.
Metrics
BasicAdvanced
Market cap
info
$5.62B
P/E ratio
info
-
EPS
info
-$0.90
Dividend Yield
info
0.00%
Beta
info
0.49
Forward P/E ratio
info
16.89
EBIDTA
info
$642M
Ex dividend date
info
-
Price & volume
Market cap
info
$5.62B
Average daily volume
info
0.5M
90-day return
info
-
30-day return
info
-
7-day return
info
-
Dividends
Dividend per share
info
$0.00
Dividend yield
info
0.00%
Forward dividend per share
info
$0.00
Forward dividend yield
info
0.00%
Payout ratio
info
0.00%
Valuation
P/E ratio
info
0
Forward P/E
info
16.89
PEG ratio
info
0.7
Trailing P/E
info
0
Price to sales
info
1.17
Price to book
info
0.87
Earnings
EPS
info
-$0.90
EPS estimate (current quarter)
info
$0.23
EPS estimate (next quarter)
info
$0.13
EBITDA
info
$642M
Revenues (TTM)
info
$4.79B
Revenues per share (TTM)
info
$13.62
Technicals
Beta
info
0.49
52-week High
info
$21.69
52-week Low
info
$13.16
50-day moving average
info
$16.39
200-day moving average
info
$17.36
Short ratio
info
3.3
Short %
info
4.89%
Management effectiveness
ROE (TTM)
info
4.53%
ROA (TTM)
info
0.96%
Profit margin
info
6.62%
Gross profit margin
info
$2.92B
Operating margin
info
6.72%
Growth
Quarterly earnings growth (YoY)
info
88.60%
Quarterly revenue growth (YoY)
info
9.10%
Share stats
Outstanding Shares
info
352M
Float
info
41.3M
Insiders %
info
88.41%
Institutions %
info
10.28%
Analyst Insights & forecasts
info

38% Buy

56% Hold

6% Sell

Based on information from 16 analysts.

Average price target

info
$19.50
Earnings per share (EPS) forecast
windowbar_chart_4_bars
Actual
info
Expected
info
Surprise
info
$0.07
$0.07
-
Q1 • 24Beat
$0.13
$0.12
8.33%
Q2 • 24Beat
$0.17
$0.16
8.97%
Q3 • 24Current
QuarterlyAnnual
Financial Performance
windowbar_chart_4_bars
Income StatementBalance SheetCash Flow
windowbar_chart_4_bars
Revenue
info
Net income
info
Profit margin
info
$1.2B
$-124M
10.37%
Q3 • 24
$1.28B
$-3M
0.23%
Q4 • 24
7.02%
97.58%
97.74%
QoQ growth
QuarterlyAnnual
Totals assets
info
Total liabilities
info
Debt to assets
info
$13.5B
$6.85B
50.71%
Q3 • 24
$13.5B
$6.93B
51.41%
Q4 • 24
0.34%
1.04%
1.38%
QoQ growth
QuarterlyAnnual
Operating
info
Investing
info
Financing
info
Free cash flow
info
$154M
$-96M
$-20M
$94M
Q3 • 24
$22M
$-185M
$146M
$-70M
Q4 • 24
85.71%
92.71%
830.00%
174.47%
QoQ growth
QuarterlyAnnual

Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Past performance is no guarantee of future results. Your return may be affected by currency fluctuations and applicable fees and charges. The value of your investment may go up as well as down. When investing, your capital at risk.

Build your future fund today!

Automate your wealth-building journey and turn investing into a habit that your future self will be grateful for!

Capital at risk.

FAQs

How much is a Bausch + Lomb Corp share?
Collapse

Bausch + Lomb Corp shares are currently traded for undefined per share.

How many shares does Bausch + Lomb Corp have?
Collapse

Bausch + Lomb Corp currently has 352M shares.

Does Bausch + Lomb Corp pay dividends?
Collapse

No, Bausch + Lomb Corp doesn't pay dividends.

What is Bausch + Lomb Corp 52 week high?
Collapse

Bausch + Lomb Corp 52 week high is $21.69.

What is Bausch + Lomb Corp 52 week low?
Collapse

Bausch + Lomb Corp 52 week low is $13.16.

What is the 200-day moving average of Bausch + Lomb Corp?
Collapse

Bausch + Lomb Corp 200-day moving average is $17.36.

Who is Bausch + Lomb Corp CEO?
Collapse

The CEO of Bausch + Lomb Corp is Brenton L. Saunders J.D..

How many employees Bausch + Lomb Corp has?
Collapse

Bausch + Lomb Corp has 13,500 employees.

What is the market cap of Bausch + Lomb Corp?
Collapse

The market cap of Bausch + Lomb Corp is $5.62B.

What is the P/E of Bausch + Lomb Corp?
Collapse

The current P/E of Bausch + Lomb Corp is null.

What is the EPS of Bausch + Lomb Corp?
Collapse

The EPS of Bausch + Lomb Corp is -$0.90.

What is the PEG Ratio of Bausch + Lomb Corp?
Collapse

The PEG Ratio of Bausch + Lomb Corp is 0.7.

What do analysts say about Bausch + Lomb Corp?
Collapse

According to the analysts Bausch + Lomb Corp is considered a hold.